News & Resources
Advancing AD Trials: Integrating Plasma Biomarkers and Imaging for Precision Enrolment
The development of blood-based biomarkers (BBMs) for early detection of Alzheimer’s disease (AD) pathology is transformative for research and drug development. Historically, diagnosis relied on symptomatic presentation with costly confirmatory imaging. Today, the field is shifting toward a biologically defined framework for earlier detection and trial stratification.
Trading update for the year ended 30 September 2025
16 October 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced a trading update, pre-audit, for its financial year ended 30 September 2025 (“FY25”).
New blood based biomarker contract win and contract extension worth a total of £1.2 million
15 October 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has signed a new commercial contract to assist in the validation of a diagnostic blood test, reaffirming the Company’s expertise in this area. IXICO has also entered into a contract extension on an existing Alzheimer’s Disease (AD) clinical trial. The combined value of the new contract and contract extension is c. £1.2 million.
Harnessing Neuroimaging in Parkinson’s Disease Clinical Trials: Best Practices and Emerging Standards
As clinical research in Parkinson’s Disease (PD) continues to evolve, neuroimaging has become a cornerstone in trial design, patient selection, and therapeutic evaluation. Across the industry, sponsors and imaging partners are adopting increasingly sophisticated imaging strategies to enhance data quality, regulatory compliance, and scientific insight.
Precision Neuroimaging in a Global Phase 1 Parkinson's Disease Clinical Trial
IXICO supported a 6-year, multinational clinical trial involving over 250 participants across more than 220 sites, delivering precision neuroimaging to assess Parkinson’s disease biomarkers.
1-8 of 177 results